Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
Theravance Biopharma is restructuring its R&D organisation and cutting its workforce by approximately half after its rare disease blood pressure drug failed to meet the primary endpoint in a Phase III study. In the CYPRESS study (NCT05696717), ampreloxetine failed to improve Orthostatic Hypotension Symptom Assessment (OHSA) composite score after eight weeks in patients with neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA). Similar trends were observed in the secondary endpoints. Change in blood pressure, heart rate and norepinephrine levels confirmed a consistent pressor effect and reaffirmed ampreloxetine's biological activity. The drug was generally well tolerated, with safety findings consistent with prior studies, including no signal of worsening of supine hypertension. CEO of Theravance, Rick Winningham, said: "We are disappointed that ampreloxetine did not meet the primary endpoint in the CYPRESS study. These results are particularly dishearte
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma (TBPH) was downgraded by Oppenheimer Holdings, Inc. from "outperform" to "market perform".MarketBeat
- Theravance Biopharma (TBPH) had its "neutral" rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.MarketBeat
- The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma (TBPH) had its price target lowered by BTIG Research from $40.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review [Yahoo! Finance]Yahoo! Finance
TBPH
Earnings
- 11/10/25 - Beat
TBPH
Sec Filings
- 3/3/26 - Form 8-K
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- TBPH's page on the SEC website